Background
- Prostate cancers with IDH1 mutations (IDH1-mt) represent a rare (<1%), potentially targetable subtype characterized by genome-wide DNA hypermethylation.
- One previous cohort of four IDH1-mt tumors identified the presence of psammomatous calcifications and anterior tumor location as pathologic features of these tumors, however clinical follow-up was not available.
- Here, we report the clinical-pathologic and molecular features for 10 IDH1-mt prostate tumors from Johns Hopkins (JH) and 35 IDH1-mt tumors from Caris, and we examine clinical outcomes in a separate group (n=24) from cBioportal.